Anti-CD20 Monoclonal Antibodies (mABs) Market size to grow by USD 11.42 billion from 2023 to 2028; North America to account for 57% of market growth- Technavio
NEW YORK, Nov. 9, 2023 /PRNewswire/ -- The Anti-CD20 monoclonal antibodies (maABs) market is expected to grow by USD 11.42 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 10.31% during the forecast period, according to Technavio Research. The market has been segmented by product (oncology, neurology, and immunology), type (first generation anti-CD20 monoclonal antibody, second generation anti-CD20 monoclonal antibody, and third generation anti-CD20 monoclonal antibody), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 57% to the growth of the global market during the forecast period. The growth of the market in North America is due to the high incidence and prevalence of hematological malignancies such as non-Hodgkin lymphoma (NHL). This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report
Company Profile:
Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.
Amgen Inc. - The company offers anti-CD20 monoclonal antibodies such as Bax active monomer recombinant antibody 6A7 OAAV00544 and CD52 recombinant antibody campath 1H OAAV00552.
To gain access to more company profiles available with Technavio, buy the report!
The market share growth by the oncology segment will be significant during the forecast period. It is the availability of anti-CD20 mAbs in common cancer indications that has driven this segment's growth.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Anti-CD20 Monoclonal Antibodies (mABs) Market: Market Dynamics
- Increased use of combination therapies
- High target affinity and specificity of anti-CD20 mABs
- Strong pipeline and recent approvals
Key Driver
Increased use of combination therapies is a key factor driving market growth. In cases where the effectiveness and poor tolerability of monotherapy products are worse than in combination therapy, a combination treatment is usually preferable. In combination with other medicines to treat comorbid diseases, the market has seen a strong increase in the use of mABs against CD20.
Major Trend
The development of CD20 bispecific antibodies is the primary trend shaping market growth. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports:
The breast cancer monoclonal antibodies market size is estimated to grow by USD 15 billion at a CAGR of 12.5% between 2022 and 2027.
The Biosimilars Market size is estimated to grow by USD 42.23 billion between 2022 and 2027, accelerating at a CAGR of 23% during the forecast period.
What are the key data covered in this anti-CD20 monoclonal antibodies (mABs) market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the anti-CD20 monoclonal antibodies (mABs) market between 2023 and 2028.
- Precise estimation of the anti-CD20 monoclonal antibodies (mABs) market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the anti-CD20 monoclonal antibodies (mABs) market across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of the anti-CD20 monoclonal antibodies (mABs) market companies.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Product
Market Segmentation by Type
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article